Radosevic Katarina, Wieland Catharina W, Rodriguez Ariane, Weverling Gerrit Jan, Mintardjo Ratna, Gillissen Gert, Vogels Ronald, Skeiky Yasir A W, Hone David M, Sadoff Jerald C, van der Poll Tom, Havenga Menzo, Goudsmit Jaap
Crucell Holland BV, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands.
Infect Immun. 2007 Aug;75(8):4105-15. doi: 10.1128/IAI.00004-07. Epub 2007 May 25.
There is an urgent need for an efficacious vaccine against tuberculosis (TB). Cellular immune responses are key to an effective protective response against TB. Recombinant adenovirus (rAd) vectors are especially suited to the induction of strong T-cell immunity and thus represent promising vaccine vehicles for the prevention of TB. We have previously reported on rAd vector serotype 35, the serotype of choice due to low preexisting immunity worldwide, which expresses a unique fusion protein of Mycobacterium tuberculosis antigens Ag85A, Ag85B, and TB10.4 (Ad35-TBS). Here, we demonstrate that Ad35-TBS confers protection against M. tuberculosis when administered to mice through either an intranasal or an intramuscular route. Histological evaluation of lung tissue corroborated the protection and, in addition, demonstrated differences between two mouse strains, with diffuse inflammation in BALB/c mice and distinct granuloma formation in C57BL/6 mice. Epitope mapping analysis in these mouse strains showed that the major T-cell epitopes are conserved in the artificial fusion protein, while three novel CD8 peptides were discovered. Using a defined set of T-cell epitopes, we reveal differences between the two mouse strains in the type of protective immune response, demonstrating that different antigen-specific gamma interferon (IFN-gamma)-producing T cells can provide protection against M. tuberculosis challenge. While in BALB/c (H-2(d)) mice, a dominant CD8 T-cell response was detected, in C57BL/6 (H-2(b)) mice, more balanced CD4/CD8 T-cell responses were observed, with a more pronounced CD4 response in the lungs. These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma.
迫切需要一种有效的抗结核疫苗。细胞免疫反应是针对结核病产生有效保护性反应的关键。重组腺病毒(rAd)载体特别适合诱导强烈的T细胞免疫,因此是预防结核病的有前景的疫苗载体。我们之前报道过35型rAd载体,由于全球范围内预先存在的免疫力较低,它是首选血清型,该载体表达结核分枝杆菌抗原Ag85A、Ag85B和TB10.4的独特融合蛋白(Ad35-TBS)。在此,我们证明,通过鼻内或肌肉内途径给小鼠接种Ad35-TBS可使其免受结核分枝杆菌感染。肺组织的组织学评估证实了这种保护作用,此外,还显示出两种小鼠品系之间的差异,BALB/c小鼠出现弥漫性炎症,而C57BL/6小鼠形成明显的肉芽肿。对这些小鼠品系进行的表位作图分析表明,主要的T细胞表位在人工融合蛋白中是保守的,同时还发现了三种新的CD8肽。使用一组确定的T细胞表位,我们揭示了两种小鼠品系在保护性免疫反应类型上的差异,表明不同的抗原特异性产生γ干扰素(IFN-γ)的T细胞可以提供针对结核分枝杆菌攻击的保护。在BALB/c(H-2(d))小鼠中检测到占主导地位的CD8 T细胞反应,而在C57BL/6(H-2(b))小鼠中,观察到更平衡的CD4/CD8 T细胞反应,在肺部CD4反应更明显。这些结果统一了关于CD4与CD8 T细胞反应在保护中的相对重要性的相互矛盾的报道,并强调了IFN-γ的关键作用。